OSPREY: 18F-DCFPyL PET/CT in Prostate Cancer

Phase 3, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by Progenics Pharmaceuticals. Primary endpoints: Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A) at 28 days and Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A) at 28 days. Started Nov 2016; status: completed.